• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.

作者信息

Kvassman J O, Lawrence D A, Shore J D

机构信息

Henry Ford Health Sciences Center, Division of Biochemical Research, Detroit, Michigan 48202-3450, USA.

出版信息

J Biol Chem. 1995 Nov 17;270(46):27942-7. doi: 10.1074/jbc.270.46.27942.

DOI:10.1074/jbc.270.46.27942
PMID:7499270
Abstract

The serpin plasminogen activator inhibitor-1 (PAI-1) spontaneously adopts an inactive or latent conformation by inserting the N-terminal part of the reactive center loop as strand 4 into the major beta-sheet (sheet A). To examine factors that may regulate reactive loop insertion in PAI-1, we determined the inactivation rate of the inhibitor in the pH range 4.5-13. Below pH 9, inactivation led primarily to latent PAI-1, and one predominant effect of pH on the corresponding rate constant could be observed. Protonation of a group exhibiting a pKa of 7.6 (25 degrees C, ionic strength = 0.15 M) reduced the rate of formation of latent PAI-1 by a factor of 35, from 0.17 h-1 at pH 9 to about 0.005 h-1 below pH 6. The ionization with a pKa 7.6 was found to have no effect on the rate by which PAI-1 inhibits trypsin and is therefore unlikely to change the flexibility of the loop or the orientation of the reactive center. The peptides Ac-TEASSSTA and Ac-TVASSSTA (cf. P14-P7 in the reactive loop of PAI-1) formed stable complexes with PAI-1 and converted the inhibitor to a substrate for tissue type plasminogen activator. We found that peptide binding and formation of latent PAI-1 are mutually exclusive events, similarly affected by the pKa 7.6 ionization. This is direct evidence that external peptides can substitute for strand 4 in beta-sheet A of PAI-1 and that the pKa 7.6 ionization regulates insertion of complementary, internal or external, strands into this position. A model that accounts for the observed pH effects is presented, and the identity of the ionizing group is discussed based on the structure of latent PAI-1. The group is tentatively identified as His-143 in helix F, located on top of sheet A.

摘要

相似文献

1
The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.
J Biol Chem. 1995 Nov 17;270(46):27942-7. doi: 10.1074/jbc.270.46.27942.
2
Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.1型纤溶酶原激活物抑制剂——通过蛋白水解敏感性探究潜伏型、活性型、反应中心裂解型和与纤溶酶原激活物复合型之间的构象差异。
Eur J Biochem. 1997 Sep 15;248(3):775-85. doi: 10.1111/j.1432-1033.1997.t01-1-00775.x.
3
Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.丝氨酸蛋白酶抑制剂(Serpins)的抑制机制:环插入促使纤溶酶原激活物抑制剂-1对纤溶酶原激活物进行酰化作用。
Biochemistry. 1998 Nov 3;37(44):15491-502. doi: 10.1021/bi9814787.
4
Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.干扰丝氨酸蛋白酶抑制剂(serpins)的抑制机制:1型纤溶酶原激活物抑制剂裂解形式与反应中心环肽形成的复合物的晶体结构
Structure. 1998 May 15;6(5):627-36. doi: 10.1016/s0969-2126(98)00064-1.
5
Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.反应中心环和β链5A的构象变化伴随纤溶酶原激活物抑制剂1的温度依赖性抑制剂-底物转变。
Eur J Biochem. 1996 Oct 1;241(1):38-46. doi: 10.1111/j.1432-1033.1996.0038t.x.
6
Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.纤溶酶原激活物抑制剂-1的底物行为与反应位点环插入缺失无关。
Biochemistry. 1996 Jun 11;35(23):7474-81. doi: 10.1021/bi960079d.
7
A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.纤溶酶原激活物抑制剂-1的荧光探针研究。反应中心环插入的证据及其在抑制机制中的作用。
J Biol Chem. 1995 Mar 10;270(10):5395-8. doi: 10.1074/jbc.270.10.5395.
8
Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.丝氨酸蛋白酶抑制剂纤溶酶原激活物抑制剂-1与组织纤溶酶原激活物及胰蛋白酶反应中米氏复合物的解离、酰化及构象变化步骤
Biochemistry. 2001 Oct 2;40(39):11742-56. doi: 10.1021/bi0107290.
9
Mutational analysis of plasminogen activator inhibitor-1.
Eur J Biochem. 2003 Apr;270(8):1680-8. doi: 10.1046/j.1432-1033.2003.03524.x.
10
The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.活性纤溶酶原激活物抑制剂-1向潜在型的转化是一个能量学上无变化的过程。
Biophys J. 2005 Apr;88(4):2848-54. doi: 10.1529/biophysj.104.053306. Epub 2005 Jan 14.

引用本文的文献

1
Identification and validation of as a prognostic and immunological biomarker in pan-cancer and in ccRCC.作为泛癌和肾透明细胞癌(ccRCC)中一种预后和免疫生物标志物的鉴定与验证
Front Pharmacol. 2023 Aug 23;14:1213891. doi: 10.3389/fphar.2023.1213891. eCollection 2023.
2
PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target.PAI-1 在糖尿病中的作用:病理生理学及作为治疗靶点的角色。
Int J Mol Sci. 2021 Mar 20;22(6):3170. doi: 10.3390/ijms22063170.
3
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.
心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
4
Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.尿激酶通过切割玻连蛋白中的RGD基序将纤溶酶原激活与细胞黏附联系起来。
EMBO Rep. 2016 Jul;17(7):982-98. doi: 10.15252/embr.201541681. Epub 2016 May 17.
5
Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites.尿激酶型纤溶酶原激活剂对上皮钠通道的蛋白水解调节:前沿进展与切割位点
J Biol Chem. 2015 Feb 27;290(9):5241-55. doi: 10.1074/jbc.M114.623496. Epub 2015 Jan 2.
6
Functional stability of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1的功能稳定性
ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15.
7
Mixture-based combinatorial libraries from small individual peptide libraries: a case study on α1-antitrypsin deficiency.来自小型个体肽库的基于混合物的组合文库:以α1-抗胰蛋白酶缺乏症为例的研究
Molecules. 2014 May 16;19(5):6330-48. doi: 10.3390/molecules19056330.
8
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.新型抗血栓药物:《抗栓治疗与血栓预防,第 9 版》:美国胸科医师学会循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e120S-e151S. doi: 10.1378/chest.11-2294.
9
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.尿激酶型纤溶酶原激活物与其抑制剂-1 识别的结构基础。
J Biol Chem. 2011 Mar 4;286(9):7027-32. doi: 10.1074/jbc.M110.204537. Epub 2011 Jan 3.
10
Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.构象敏感配体揭示的1型纤溶酶原激活物抑制剂活性形式之间的结构差异。
J Biol Chem. 2008 Jun 27;283(26):18147-57. doi: 10.1074/jbc.M709455200. Epub 2008 Apr 24.